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Abstract 
BACKGROUND: Angiogenesis plays a pivotal role in the progression of tumours through the formation of new 
blood vessels. Vascular endothelial growth factor (VEGF) is a chief factor responsible for inducing and regulating 
angiogenesis. Additionally, the human epidermal growth factor receptor family of receptors also plays an 
important role in the pathogenesis of tumours.  
AIM: This study aimed to examine the association between VEGF and Her-2 protein expression and its 
correlation with clinic-pathological characteristics; in particular, prognosis.  
METHODS: A total of 65 cases of cervical carcinoma and 10 samples of inflammatory lesions were evaluated for 
VEGF and Her-2 protein expression.  
RESULTS: Expression of VEGF and Her-2 was detected in 63.07% and 43.07% in cervical carcinoma cases 
respectively whereas control cases did not show any expression. The difference in the expression pattern of both 
markers comparing cancer and control cases was statistically significant (p < 0.05). However, no significant 
difference in the expression pattern of VEGF protein was observed among the different grades and stages of 
tumours (p > 0.05). Comparing different grades of a tumour, expression of Her-2 was detected in 31.8% of well-
differentiated tumours, 36.0 % in moderately differentiated tumours and 66.66 % in poorly differentiated cancers. 
The expression of Her-2 was increased in high-grade tumours, and the difference of expression level between 
tumour grades was statistically significant (p < 0.05). The expression level of Her-2 protein was not correlated with 
the stage of a tumour (p > 0.05).  
CONCLUSION: The present study supports earlier findings that over-expression / up-regulation of VEGF and Her 
- 2 is linked with poor prognosis and may play a vital role in the development and progression of cervical cancer. 
 
 
 
Introduction 
 
Cervical cancer is the most common form of 
female genital malignancy and is a principal cause of 
cancer-associated mortality. Despite numerous 
studies, the exact carcinogenetic events in the 
development and progression of cervical cancer are 
not entirely understood. In this regard, hormonal 
imbalance, smoking and obesity are suggested to be 
the chief causative agents in the development and 
progression of cervical cancer. Additionally, Human 
Papillomavirus (HPV) has been recognised as an 
etiological agent in the pathogenesis of uterine cervix 
cancer [1][2] and epidemiological studies have shown 
that HPV infection is commonly identified in invasive 
cervical cancer [3].  
Angiogenesis has also been shown to play 
a vital role in tumour development and progression 
through the formation of new blood vessels. 
Vascular endothelial growth factor (VEGF) acts as 
the chief mediator of tumour angiogenesis and 
stimulates the growth of new blood vessels [4]. It 
has been shown that VEGF plays an important role 
in inducing angiogenesis in some physiological and 
pathological processes [5]. Moreover, VEGF 
expression may be induced by various factors such as 
altered expression of tumour suppressor genes [6], 
oncogenes [7][8], insulin-like growth factor – 1 [9] and 
altered VEGF expression has been associated with 
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both the advanced pathological stage of cancer and 
lymph node metastasis [10]. 
The human epidermal growth factor receptor 
2 (Her2) is a transmembrane receptor tyrosine kinase 
[11][12] and has been shown to play a significant role 
in the pathogenesis of tumours. Her2-gene 
amplification appears to be an early event in the 
development of cancer [13]. Up-regulation of Her-2 
has been noticed in the genesis of numerous cancers 
including cervical cancer.  
The current study aimed to examine the 
expression patterns of VEGF and Her-2 proteins in 
cervical cancer and correlate the expression pattern of 
both markers with clinic-pathological features 
observed in patients. 
 
 
Materials and Methods 
 
Patients and tissues 
Tissue from a total of 65 patients (mean age 
65 ± 14 years, range 26 – 98 years) diagnosed with 
cervical carcinoma was collected from the 
Histopathology Department at the National Health 
Laboratory (and other histopathology laboratories) in 
Sudan. A total of 10 cases of inflammatory lesions of 
the cervix were included in the study as a control 
group. The study was approved by the institutional 
Research Ethics Committee, and written consent was 
obtained from each patient. Hematoxylin and Eosin 
(H&E) staining were performed on each case to 
evaluate the histopathology of tissue samples, 
including grade and stage of a tumour (Figure 1). The 
detailed clinic-pathological feature of the patients is 
presented in Table 1. A series of 5 – μm -thick 
sections were prepared from each formalin-fixed, 
paraffin-embedded block and immunohistochemical 
staining was performed to evaluate the expression 
pattern of VEGF and Her-2 protein to allow its 
interpretation and correlation with clinical outcome. 
 
Figure 1: Section from cervical carcinoma grade II(H & E X40) 
Table 1: Correlation between VEGF and clinicopathological 
features in cervical carcinoma 
Variables  Total 
cases 
VEGF positive VEGF negative the  
Cervical carcinoma 65 41 (63.07%) 24 (36.92%) < 0.05 
Inflammatory lesion 10 0 (0%) 10 (100%) 
Age (In years) 
≤ 55 years 
> 55 years 
 
 
28 
 
16 (57.14%) 
 
12 (42.85%) 
 
> 0.05 
 37 25 (67.56%) 12 (32.43%) 
Histological grades  
Well differentiated 22 12 (54.54%) 10 (45.45%)  
 
> 0.05 
Moderately differentiated 25 17 (68.00%) 14 (32.55%) 
Poorly differentiated 18 12 (66.66%)  
Histologic type  
Squamous Cell Carcinoma 59 38 (64.4%) 21 (35.59%)  
> 0.05 Adenocarcinoma  6 3 (50.0%) 3 (50.0 %) 
Clinical stage   
I 14 7 (50.0%) 7 (50.0%) > 0.05 
II 17 11 (64.7%) 6 (35.29%) 
III and IV 34 23 (67.64%) 11 (32.35%) 
 
 
Immunohistochemical staining 
Five μm sections from each paraffin-
embedded tissue block were prepared from cervical 
cancer and inflammatory lesions. 
Immunohistochemical staining was performed on 
paraffin-embedded tissue sections as described by 
Rahmani et al., 2015 [14]. In brief, deparaffinization of 
all sections was made through a series of xylene 
solutions, and rehydration was performed through 
graded ethanols. Also, endogenous peroxidase 
activity was blocked by pre-treatment of sections with 
0.3% hydrogen peroxide for 20 minutes. Antigen 
retrieval was performed using a sodium-citrate buffer 
(pH 6.0), in a microwave oven for 30 minutes. 
Additionally, protein blocking agent (Abcam, USA) 
was applied for 10 minutes to reduce nonspecific 
binding. VEGF and Her-2 antihuman monoclonal 
antibodies (Abcam, Cambridge, MA, USA) were used 
as primary antibodies followed by the secondary 
biotinylated antibody (Abcam, USA). Detection of 
immunostaining for VEGF and Her-2 protein was 
performed using the streptavidin-biotin 
method. Diaminobenzidine (DAB) chromogen 
(Abcam, USA) was applied then sections were 
counterstained and mounted with DPX. Negative 
controls (omission of primary antibody) and positive 
controls were used to verify the quality of staining. 
 
Staining Interpretation 
Expression of VEGF and Her-2 protein was 
evaluated, and the mean percentage positivity was 
calculated. Five fields from each section were 
selected, and positive cells for each marker (lowest to 
the highest number of positive cells) were counted at 
40 X magnification. Specimens were considered as 
positively stained when more than 10% of the tumour 
cells showed cytoplasmic expression for VEGF and 
membranous or cytoplasmic stain for Her2 protein. If 
10% or less than 10 % of cells showed cytoplasmic 
expression, they were classified as negative cases.  
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Statistical analysis 
Expression of markers was correlated with 
clinicopathological features of the patients. Chi-square 
(λ)
2
 test was used to make the correlation of marker 
with grade, age and stage of the tumour. Statistical 
significance was defined as p < 0.05. 
 
 
Results 
 
Association of VEGF protein expression 
with clinicopathological characteristics 
The expression pattern of VEGF was 
examined in uterine cervix cancer including squamous 
cell carcinoma (SCC), adenocarcinoma and 
inflammatory lesions of the cervix. The expression of 
VEGF was detected only in the cytoplasm of cancer 
cells (Figure 2, a-c) whereas control cases did not 
show any expression. VEGF protein showed 
expression in fewer than 10% of cells or no 
expression in all ten inflammatory lesions and these 
were thus considered as negative for VEGF 
expression.  
 
Figure 2: a) Immunohistochemical staining of VEGF protein demonstrating 
strong cytoplasmic expression in a cervical carcinoma (Orig mag. 40X); b) 
Immunohistochemical staining of VEGF protein showing moderate 
cytoplasmic expression in a cervical carcinoma(Orig mag. 40X); c) 
Expression of VEGF protein in section from carcinoma of cervix(Orig mag. 
40X) 
 
Conversely, greater than 10% positivity for 
VEGF staining was observed in 41/65 (63.07%) cases 
of cervical cancer patients, and these were 
considered VEGF positive. The difference in VEGF 
expression between cancer cases and control cases 
was statically significant (p ≤ 0.05). Moreover, the 
expression level for VEGF was correlated with tumour 
grade was found to be positive in 12/22 (54.54%) well-
differentiated tumours, 17/25 (68.00%) samples of 
moderately and 12/18 (66.66%) poorly differentiated 
carcinoma. The difference in VEGF expression 
between different grades of a tumour did not reach 
statistical significance (р > 0.05) (Table 1), and 
intensity of expression was high in poorly 
differentiated carcinoma as compared to well and 
moderately differentiated carcinoma. 
Additionally, the expression of VEGF was 
evaluated according to the stage of cancer, and it was 
found that VEGF expression was positive in 7/14 
(50%) Stage I samples, 11/17 (64.7%) stage II 
samples and 23/43 (67.64%) stage III and IV samples 
(Table 1). The difference of VEGF expression 
observed in the different tumour stages was also 
found to be statically insignificant (р > 0.05). The 
expression of VEGF was also correlated with the age 
of the patients (younger than 55 years and equal or 
older than 55 years). Again, no significant difference 
was observed between samples from different age 
groups.  
 
Expression pattern of Her-2 protein in 
cervical cancer and inflammatory lesions 
Her-2 protein was not detected in 
inflammatory lesions of the cervix while there were 
strong expression observed in 28/65 (43.07%) 
carcinoma cases (Figure 3) (p < 0.05). Expression 
analysis of Her-2 protein in different tumour grades 
showed that Her-2 expression was increased with a 
grade of a tumour. Her-2 expression was detected in 
7/22 (31.8%) well-differentiated tumours, 9/25 (36.0 
%) moderately differentiated tumours and 12/18 
(66.66 %) poorly differentiated cancers (Table 2). Her-
2 expression showed a significant difference in 
expression between different grades of cancer 
(p < 0.05). 
 
Figure 2: Immunohistochemical expression of Her-2 protein in poorly 
differentiated cervical carcinoma (Orig Mag. 40X) 
 
 The immunoreactivity of Her-2 was not found 
to be correlated with stage of a tumour, Her-2 
expression observed in 6/14 (42.85%) Stage I, 11/17 
(64.7%) Stage II and 17/34 (50.0%) Stage III/IV 
tumours (Table 2). Moreover, the expression profile of 
Her-2 protein also showed no significant difference 
between different age groups of patients (≤ 55 years 
and > 55 years). 
Table 2: Correlation between Her-2 protein and 
clinicopathological features of cervical carcinoma 
Variables  Total 
cases 
Her-2 positive Her-2 negative p - value 
Cervical carcinoma 65 28 (43.07%) 37 (56.92%) < 0.05 
Inflammatory lesion 10 0 (0%) 10 (100%) 
Age (In years) 
≤ 55 years 
> 55 years 
 
28 
 
11 (39.28%) 
 
17 (60.71%) 
 
> 0.05 
37 17 (45.94%) 20 (54.05% 
Histological grades  
Well differentiated 22 7 (31.8%) 15 (68.18%)  
< 0.05 Moderately differentiated 25 9 (36.0%) 16 (64%) 
Poorly differentiated 18 12 (66.66%) 6 (33.33%) 
Histologic type  
Squamous Cell Carcinoma 59 25 (42.37%) 34 (57.62%)  
> 0.05 Adenocarcinoma  06 3 (50.0%) 3 (50%) 
Clinical stage   
I 14 6 (42.85%) 8 (57.14%) > 0.05 
II 17 11 (64.7 %) 06 (35.29%) 
III and IV 34 17 (50.0%) 17 (50.0%) 
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Relationship between VEGF protein 
expression, and Her 0-2 expression with 
clinicopathologic features 
Both proteins VEGF and Her-2 showed high 
levels of expression in cancer cases while none of the 
control lesions that were studied showed positive 
expression. The difference in expression for both 
markers comparing cancer cases and control cases 
were thus statically significant. Furthermore, the 
immunoreactivity of Her-2 marker increased according 
to grades of a tumour whereas VEGF did not show a 
significant difference in expression when comparing 
tumour grade. Both markers did not show any 
significant difference in the level of expression when 
comparing different age groups of patients. 
 
 
Discussion 
 
Angiogenesis is the process of formation of 
new blood vessels from sprouting of existing vessels. 
Extensive laboratory data suggests that new vessel 
formation is an important step in driving tumour 
growth and progression [15][16][17]. Vascular 
Endothelial Growth Factor (VEGF) is one of the chief 
angiogenic factors that stimulate the formation of new 
blood vessels and thus can influence tumour growth 
[18]. Previous studies have confirmed that over-
expression of VEGF can be correlated with tumour 
growth, metastasis and patient survival [19][20][21]. 
Altered expression of VEGF has been observed in 
cancers and strongly suggesting that angiogenesis 
participates in tumour development and progression. 
In the current study, it was found that VEGF 
expression was high in 41 (63.07%) in cervical 
carcinoma cases while inflammatory lesions did not 
show detectable expression. The difference in 
expression of VEGF in cancer cases and control 
cases was found to be statistically significant 
(p < 0.05). These findings are consistent with an 
earlier study on cervical cancer, which reported that 
VEGF was not expressed in control tissue samples 
whereas VEGF expression was high in patients with 
high-grade squamous intraepithelial (HSIL) lesions 
(33.33%) and patients with cervical cancer (60.87%) 
[22], showing a statistically significant difference 
between tumour samples and control [22].  
Another study also reported that VEGF 
expression progressively increased along a continuum 
from normal epithelium to invasive SCC [23]. Our 
findings showed that immunostaining was high in 
high-grade tumours and slightly increased according 
to the grade of a tumour, this difference was not 
statistically significant (p > 0.05). A study examining 
transitional cell carcinoma of the urinary bladder 
reported that VEGF immunostaining was positively 
correlated with grade, stage, and recurrence of 
transitional cell carcinoma but the findings were not 
statistically significant [24] while another study on 
urinary bladder carcinoma showed that the rate of 
VEGF expression increased significantly with the 
progression of tumour grade [25]. An earlier report 
looking at cervical cancer stated that high VEGF 
immunostaining was observed in grade III cervical 
intraepithelial neoplasia whereas expression was 
found to be low in grade I cervical intraepithelial 
neoplasia and in control group samples [26]. Lastly, 
an earlier study also found that there was no 
significant difference between VEGF expressions in 
tumours of various grades of differentiation [27]. 
 In the current study, the expression of VEGF 
protein was analysed in different age groups of the 
patients (≤ 55 years and > 55 years), and it was found 
that there was no significant difference between age 
groups (р > 0.05). A previous study also reported no 
correlation between age and VEGF positive tumours, 
with the number of VEGF positive tumours in patients 
<50 years 58.0 %, while 50-55 years showed 63.75%, 
and >55 years was 52.9%, all of these differences 
showing no statistical significance [27]. 
Her-2 belongs to the family of HER genes that 
control cell growth, survival, differentiation and 
migration [28][29]. Her-2 over-expression has been 
noticed in invasive breast cancers [30], gastric cancer 
[31] and previous studies examining cervical cancer 
reported that 29.7% tumours expressed the c – erbB-
2 (Her-2) protein [32]. The present study was also 
aimed to measure the expression of Her-2 in cervical 
cancer, and positive immunostaining was observed in 
28 (43.07%) cases while the control group did not 
show any expression. This is similar to a previous 
study examining lesions of the uterine cervix, which 
reported that higher expression of Her-2/neu was 
noticed in malignant lesions as compared to benign 
lesions [33]. Moreover, expression of the Her-2 
protein was found to be higher in high-grade tumours 
when compared to low-grade tumours. The difference 
of Her-2 expression between the tumour grades was 
found to be statistically significant (p < 0.05) in this 
study. Furthermore, an earlier study reported that 
malignancies exhibited a variable degree of Her-2 
expression with significantly higher expression 
observed in high-grade squamous cell carcinomas 
[33]. Lastly, another study reported similar findings 
where benign, premalignant and malignant cervical 
tissues showed a highly significant correlation 
between the expression of the epidermal growth factor 
receptor (EGF-R), the oncogene product of c–erbB-
2 and the histological grade of the lesion [34]. In the 
current study, immunoreactivity of Her-2 was not 
correlated with stage of a tumour. This differs from 
two previous reports that showed Her-2 positivity was 
higher in Stage III (87.50%) and stage IV (100%) 
tumors as compared to stage I (48.28%) and Stage II 
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(72.22%) [33]; and that stronger Her-2/neu expression 
were observed in higher stage tumors [35]. 
The present study supports earlier findings 
that overexpression/up-regulation of VEGF and Her-2 
protein in cervical cancer are linked to poor prognosis 
and that expression of these proteins may play vital 
roles in the development and progression of cervical 
cancer. 
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